01

Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”), we wish to inform you that the Board of Directors (“Board”) of Brooks Laboratories Limited (“Company” or “Demerged Company”), based on the recommendations of the Audit Committee and the Committee of Independent Directors, at its meeting held today, i.e.

Page 1

02

October 14, 2026, has approved the Scheme of Arrangement between the Company, Abridge Speciality Limited (“Resulting Company”) and their respective shareholders, under Sections 230 to 232 and other applicab le provisions of the Companies Act, 2013 and other appl icable regulatory requirement s, for the demerger of the Manufacturing Business (“Manufacturing Business”) of the Demerged Company into the Resulting Company (“Scheme”).

Page 1

03

The Scheme is subject to the requisite approvals of the Stock Exchanges, Securities and Exchange Board of India, NCLT and other regulatory/statutory authorities, as applicable, and the approval of the shareholders and/or creditors of the Company and the Resulting Company, as may be directed by the NCLT or otherwise required under applicable law.

Page 1

04

Upon effectiveness of the Scheme, the name of th e Resulting Company shall be changed to Brooks Laboratories Limited and the name of the Demerged Company shall be changed to Xuri Lifesciences Limited or such other name as may be approved by the Registrar of Companies.

Page 1

05

The aforesaid meeting of the Board of Directors of the Company commenced at 4.00 PM (IST) and concluded at 5:30 PM (IST).

Page 2